Theravance Pushes On With Gastroparesis Candidate Amid Mixed Data

Theravance is working out what to do next with its investigational drug for gastroparesis after it produced mixed data in a Phase IIb trial in this underserved indication.

Theravance Biopharma Inc. believes its highly selective 5HT-4 receptor agonist, velusetrag (TD-5108), has potential as a new treatment for gastroparesis – or delayed stomach emptying – on the back on Phase IIb data where only the lowest dose tested reached significance in the primary endpoint.

The company is now preparing to meet regulators to discuss the next phase in its development plan for the product....